The Depo-Provera multidistrict litigation has reached a size that should command the attention of more than litigation teams.
As of July 1, 2026, the Judicial Panel on Multidistrict Litigation reported 5,830 pending actions in MDL No. 3140. That represented an increase of 322 pending cases from the 5,508 reported one month earlier, or approximately 5.8%.
The July report also listed Depo-Provera as the ninth-largest active federal MDL by pending case count.
For mass tort firms, those numbers can be viewed as an operational signal. They reflect substantial filing activity, but docket size alone does not establish the strength, value or likely outcome of individual claims.
A rapidly expanding MDL can create pressure to increase advertising, answer more calls and sign claimants quickly. Growth, however, can also increase the cost of weak qualification. When intake teams focus primarily on lead and signature volume, firms may accumulate cases without the evidence, records or claimant participation necessary to satisfy litigation requirements.
The firms best positioned to manage the next phase of the Depo-Provera litigation may not necessarily be those generating the most leads. They may be the firms that can convert potentially eligible claimants into well-documented, filing-ready cases.
The Depo-Provera MDL Now Includes Formal Threshold-Proof Requirements
The federal litigation was centralized in the Northern District of Florida on February 7, 2025, before Judge M. Casey Rodgers.
The cases share allegations involving injectable Depo-Provera or certain generic equivalents and the subsequent development of meningiomas. The defendants dispute the claims and maintain that the medication is safe and effective.
The litigation remains contested. The size of the docket and the existence of threshold-proof requirements do not determine general causation, specific causation, liability, damages or the ultimate merits of any individual case.
From an intake perspective, however, an important development is that the court has established concrete documentation requirements for filed plaintiffs.
Under Pretrial Order No. 17, plaintiffs with filed cases must provide initial documentary proof of their use of the product attributed to each named defendant, as well as documentary proof of the alleged meningioma injury.
The required questionnaire and supporting materials are submitted through the BrownGreer MDL Centrality system. For cases filed in or transferred into the MDL after entry of the order, the submission deadline is generally 120 days from filing or transfer. Extensions are subject to the procedures established by the court.
These requirements may justify a more evidence-focused internal definition of case readiness.
A claimant’s recollection may support further investigation, but recollection alone should not automatically be treated as filing readiness. An intake workflow should evaluate not only whether the claimant’s account appears to match current litigation criteria, but also whether the firm can locate and obtain the documentation necessary to support that account.
Intake Should Become Evidence-First, Not Signature-First
Traditional high-volume intake often emphasizes speed to contact and speed to signature. Those measurements remain important, particularly when multiple firms are competing to reach the same potential claimant.
In an MDL with threshold-documentation requirements, however, speed without evidence controls can create downstream risk.
Pretrial Order No. 22 identifies the information that must appear in a threshold-proof submission.
Proof of use must identify the plaintiff, include a relevant date, identify an accepted product and contain information showing that the product was prescribed, dispensed, administered, reimbursed or otherwise provided to the plaintiff.
Proof of injury must identify the plaintiff, establish a qualifying meningioma diagnosis and provide the diagnosis date. The order also contains specific terminology and timing requirements that should be reviewed when preparing a submission.
The order imposes detailed formatting standards as well. Plaintiffs may generally submit no more than five pages for each product and no more than five pages for each diagnosis. The pages relied upon must be bookmarked as required by the order.
These requirements mean that obtaining a large medical or pharmacy file is not the same as preparing an adequate threshold submission. A firm must identify the pages containing the required information, confirm that the documents correspond with the claimant’s questionnaire answers and submit the records in the prescribed format.
A threshold submission accepted as complete does not necessarily establish that the evidence will be sufficient at summary judgment or trial. The process is an initial case-management requirement, not a final determination of proof.
A more effective intake model may separate claimants into three operational stages:
Potentially Eligible Lead
The individual’s preliminary answers suggest that the potential claim warrants additional investigation.
Evidence-Qualified Claimant
The firm has identified viable sources for proof of product use and proof of injury.
Filing-Ready Case
The required documents have been obtained, reviewed, organized and matched to the claimant’s answers and the court’s current submission requirements.
Separating these stages can give firm leadership a more accurate understanding of inventory quality.
Records Procurement Should Begin During Intake
In mature MDLs, medical-record collection is often treated as a post-signup case-management function. For Depo-Provera claims, firms should consider moving part of that work closer to the initial intake stage.
Intake teams can identify the providers, pharmacies, health systems and insurers most likely to possess relevant documentation. They can also determine whether those entities still exist, how far back their records extend and whether the claimant can provide portal access, insurance history or other information that may accelerate the search.
A records-focused intake process may capture details such as:
- Approximate dates and locations of Depo-Provera use
- The prescribing or administering provider
- The dispensing pharmacy, when applicable
- Insurance carriers during the relevant periods
- The facility and physician associated with the meningioma diagnosis
- The date of diagnosis, imaging and treatment
- Prior attempts to obtain relevant records
- Changes in the claimant’s name, address or insurance information
The objective is not to turn intake specialists into medical-record reviewers. It is to ensure that the records team begins with usable information rather than having to reconstruct the claimant’s medical and prescription history weeks or months later.
Older Product Use Requires Its Own Workflow
Depo-Provera presents an additional operational challenge because some alleged use occurred many years ago.
Providers may have closed, pharmacies may have changed ownership and records may no longer be available through ordinary retrieval channels.
The court has recognized this issue.
Pretrial Order No. 22A established a limited threshold-deficiency exception for certain plaintiffs whose sole alleged use occurred before June 2005 and who cannot obtain the otherwise required proof of use.
To use the exception, a plaintiff must provide a declaration and document diligent attempts to request records from identified providers, pharmacies or other entities.
The exception does not eliminate the obligation to investigate and document those efforts. It also applies only to the current threshold-deficiency process. Defendants remain free to argue at a later stage that the declaration and supporting materials are insufficient to prove product use.
This makes a separate remote-use workflow operationally valuable.
Cases involving older alleged exposure can be flagged during intake and routed into an expanded records process. Depending on the circumstances, that process may require:
- Research into closed or reorganized medical practices
- Archived insurance searches
- Pharmacy ownership research
- Correspondence and follow-up tracking
- Documentation of unsuccessful retrieval attempts
- Preparation of declarations that accurately describe the claimant’s knowledge and the firm’s records-search efforts
Waiting until a deficiency notice arrives to begin that work may leave the firm with limited time to investigate and respond.
Filing Volume Should Be Controlled by Evidence Readiness
The Depo-Provera MDL permits eligible cases to be filed directly in the Northern District of Florida for coordinated pretrial proceedings.
Direct filing may avoid the need for an initial transfer into the MDL, but it does not eliminate or reduce the threshold-documentation requirements applicable to filed plaintiffs.
As an internal best practice—not as a separate court-mandated checklist—firms may consider conducting a prefiling readiness review addressing whether:
- The claimant’s answers are internally consistent
- A potentially qualifying product has been identified
- Proof of use has been obtained or a documented retrieval strategy is active
- The alleged injury and diagnosis date are supported by available records
- The appropriate defendant or defendants have been evaluated
- The required documents can be submitted in the prescribed format
- Court and internal deadlines have been entered into the case-management system
- The claimant remains responsive and understands future participation requirements
This review does not need to slow every case equally.
Firms can create different processing lanes based on evidence status and case complexity. A claimant with accessible pharmacy and diagnostic records may move rapidly. A claimant alleging product use decades ago may require additional development before the firm makes a filing decision.
The important operational shift is that filing decisions should reflect evidence readiness, not simply signed-contract volume.
Firms Need Operational Metrics That Measure Case Quality
Lead totals and signed retainers provide only a partial picture of performance in a growing MDL.
Leadership should also consider monitoring:
- Percentage of signed claimants with verified proof of use
- Percentage with verified proof of injury
- Average time from signature to the first records request
- Average time from records request to receipt
- Percentage of cases entering a deficiency process
- Claimant response rates for questionnaires, authorizations and signatures
- Percentage of inventory classified as filing-ready
- Cost per evidence-qualified claimant
- Cost per filing-ready case
These measurements can reveal whether marketing and intake are producing viable inventory or primarily shifting unresolved qualification and documentation work to the litigation team.
They can also improve campaign decisions.
A source generating inexpensive leads may become less attractive when evaluated against proof rates, claimant responsiveness and filing readiness. Conversely, a higher-cost source may deliver better-documented claimants and reduce the firm’s long-term operational burden.
Growing MDLs Reward Disciplined Intake Systems
The increase to 5,830 pending cases shows substantial filing activity within the Depo-Provera MDL.
It does not mean that every inquiry is a viable case, nor does it determine the merits, value or eventual outcome of individual claims.
For plaintiff firms, the strategic opportunity is to connect claimant acquisition with the actual procedural and documentation requirements of the litigation.
Marketing, intake, records procurement and legal review should operate as one coordinated system rather than as separate departments handing unresolved problems downstream.
SmashOrbit Legal supports plaintiff firms with client-acquisition strategy, campaign execution and AI-supported performance analysis. Its approach can incorporate evidence-readiness and claimant-quality indicators alongside traditional lead and signed-retainer metrics, helping firms evaluate acquisition performance against the operational realities of building better-documented mass tort inventories.
Want to learn more about developing a more evidence-focused Depo-Provera acquisition and intake strategy?
Contact SmashOrbit Legal to discuss how your firm can pursue growth while maintaining greater control over claimant qualification, documentation and case readiness.